Trial ID: | L1206 |
Source ID: | NCT02047708
|
Associated Drug: |
Zibotentan
|
Title: |
Zibotentan Better Renal Scleroderma Outcome Study
|
Acronym: |
ZEBRA
|
Status: |
COMPLETED
|
Study Results: |
NO
|
Results: |
|
Conditions: |
Scleroderma|Scleroderma Renal Crisis|Chronic Kidney Disease
|
Interventions: |
DRUG: Zibotentan
|
Outcome Measures: |
Primary: sVCAM 1 soluble Vascular Cell Adhesion Molecule, sVCAM1 is a biomarker of renal involvement in scleroderma, 12 months |
|
Sponsor/Collaborators: |
Sponsor: University College, London | Collaborators: Medical Research Council
|
Gender: |
ALL
|
Age: |
ADULT, OLDER_ADULT
|
Phases: |
PHASE2
|
Enrollment: |
27
|
Study Type: |
INTERVENTIONAL
|
Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
Start Date: |
2014-10
|
Completion Date: |
2017-10
|
Results First Posted: |
|
Last Update Posted: |
2017-10-31
|
Locations: |
Royal Free London NHS Foundation Trust, London, NW32QG, United Kingdom
|
URL: |
https://clinicaltrials.gov/show/NCT02047708
|